Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07761702 | Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML | not yet recruiting | Phase 3 | 132 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | recruiting | Phase 2 / Phase 3 | 324 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04827719 | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS | completed | Phase 2 | 38 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05457010 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | active not recruiting | Phase 1 | 24 | Arcellx, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06159491 | Pacritinib in CMML | recruiting | Phase 1 / Phase 2 | 26 | Douglas TremblayOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | not yet recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT00935090 | 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | active not recruiting | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT03744390 | IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | recruiting | Phase 1 / Phase 2 | 86 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 160 | Incyte CorporationINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT06285890 | Phase I Study of HC-7366 for Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06361641 | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes(PHEMOP) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial | suspended | Phase 1 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06529250 | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML(HADCEBPA2023) | recruiting | N/A | 148 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07131059 | MRD-positive AML Clinical Study | recruiting | N/A | 537 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07681258 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region(ASC4Young) | not yet recruiting | — | 80 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia(GAVE001) | not yet recruiting | Phase 2 | 20 | Florian KuchenbauerOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756034 | Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer(ONCO-OLIVIA) | recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02071901 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | completed | Phase 2 | 31 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03573024 | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | completed | Phase 2 | 36 | University of Colorado, DenverOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06265545 | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | recruiting | N/A | 458 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | recruiting | Phase 3 | 284 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07061145 | A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia(ED2024) | recruiting | — | 350 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07490288 | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | recruiting | N/A | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | not yet recruiting | — | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751991 | A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | recruiting | Phase 1 | 40 | Charm TherapeuticsINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752121 | First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms(LUNIS) | not yet recruiting | — | 190 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03253848 | Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia | active not recruiting | N/A | 202 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06456463 | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy(TRILLIUM) | active not recruiting | Phase 2 | 85 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT06609928 | FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 120 | Incyte CorporationINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT07425782 | Venetoclax Combined With Azacitidine for Consolidation Therapy in AML | recruiting | Phase 2 | 216 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07670130 | Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis(ND-AML) | recruiting | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07672262 | VA Consolidation in Intermediate-Risk AML | recruiting | Phase 2 | 226 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07743047 | Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality(SynT) | not yet recruiting | — | 65 | IRCCS San RaffaeleOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT04281199 | TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06006403 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | completed | Phase 1 / Phase 2 | 5 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06641648 | A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. | recruiting | Phase 1 | 12 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | recruiting | Phase 2 / Phase 3 | 312 | Moleculin Biotech, Inc.INDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | recruiting | Phase 2 / Phase 3 | 24 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07740603 | Study of CD38 and CD56 in Chronic Myeloid Leukemia | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 12, 2026source: clinicaltrials